Sector News

GE Healthcare’s CEO John Dineen to step down

October 9, 2014
Life sciences
GE Healthcare is changing up its leadership Monday, with current president and CEO John Dineen stepping down, effective immediately.
 
The top role will be filled by John Flannery, who was most recently the senior vice president of business development for GE, the company said.
 
The leadership shift is the latest to take place under chairman and CEO Jeff Immelt. Over the past 15 months, Immelt replaced top leaders at GE Capital and GE Oil & Gas and named Jeff Bornstein as the new chief financial officer of GE.
 
Dineen led the $20 billion health unit for seven years and worked within GE for 28 years. He previously held senior positions in GE Industrial Systems, Plastics, Transportation and Healthcare. Dineen is leaving the company to explore “new leadership opportunities,” according to the statement.
 
“John successfully led GE Healthcare during a period of growth, portfolio diversification and market volatility,” Jeff Immelt, GE chairman and CEO, said. “Thanks to his leadership, the business today is a global leader.”
 
GE Healthcare is the world’s leading manufacturer of medical imaging devices and also specializes in medical diagnostic tools and healthcare IT and software.
 
Flannery has been a key deal maker at GE this past year. He had a central role in GE’s recent purchase of France-based Alstom’s energy and transmission business as well as the spinoff of the company’s retail finance division, Synchrony Financial, which went public this year. He was also previously president and CEO of GE India and a senior leader at GE Capital.
 
By Laura Lorenzetti 
 
Source: Fortune

comments closed

Related News

October 17, 2021

Colorcon acquires a majority share in Ideal Cures Pvt. Ltd., India

Life sciences

Ideal Cures will operate as a fully independent entity within Colorcon. Their business complements Colorcon’s position in the Indian pharmaceutical market with a strong presence in the domestic generic sector comprised of long-standing customer relationships sustained by innovative and customized solutions.

October 17, 2021

Barriers exist, but participation urgent in breast cancer clinical trials: report

Life sciences

Across four new breast cancer treatments approved by the FDA last year, 2% to 9% of patients in clinical trials for the drugs were Black Americans and 0% to 9% were Hispanic, according to a new report from Breastcancer.org.

October 17, 2021

Danish consortium acquires part of Jernbanebyen to create one of the world’s healthiest urban villages

Life sciences

The southern section of Jernbanebyen in central Copenhagen has a new owner. The Baneby Consortium, comprising NREP, Novo Holdings and Industriens Pension, has bought the land from Freja Ejendomme. The ambition is to create a green, partly car-free environment that will also be one of the healthiest in the world. 

Send this to a friend